DnaK Therapeutics
01 / TeamNine people

The scientists who made the discovery still lead the science.

Dr Robert C. Gallo, Dr Davide Zella and Dr Francesca Benedetti co-founded the company and still run its research. Several people here hold more than one role; each is listed once, in their most senior grouping, with every role named.

04Corporate leadership
05Scientific leadership
07Board of directors
09People profiled

Corporate leadership

Dipak Thakker

Co-chair of the board · Chief financial officer

As Co-Chair of the Board and Chief Financial Officer of DnaK Therapeutics, Mr Thakker brings more than two decades of experience in operations, management and general administration. He is CEO and CIO of Stellar Venture Partners and a co-founder of Stellar iDea Labs. Earlier in his career he rose to Director at FINRA, where he led research and development of predictive analytics using regression and artificial intelligence to detect insider trading and fraud across Nasdaq, NYSE and Amex. He is also a hospitality entrepreneur through his ownership of hotels and food establishments, and serves on The Universities of Shady Grove Entrepreneurship Lab Advisory Council. He holds an MBA in Finance and Investment Management from the University of Maryland's Robert H. Smith School of Business, an MS in Software Engineering from Gujarat University, and a BS in Math and Physics from Gujarat University.

Mathew Evins

Co-chair of the board · Senior strategic advisor

Mathew L. Evins is a distinguished and accomplished business professional, healthcare executive and branding expert recognized for his commitment to excellence as well as his erudite and purposeful leadership. Mathew is also recognized for his creative and strategic prowess, and his ability to navigate complex challenges. Mr. Evins serves as the Chairman and Founder of Evins Communications as well as CEO, Treasurer, Emeritus Executive Chair and founding board member of the Global Virus Network. Mr. Evins has built a distinguished career encompassing corporate finance, marketing communications, medicine and science, and is committed to making a positive and lasting contribution to the organizations, communities and individuals he serves.

Joshua Sircus

Acting chief executive officer · Chief operating officer · Board

As Acting Chief Executive Officer and Chief Operating Officer of DnaK Therapeutics and a board member, Mr Sircus brings 25+ years of experience building teams in finance and technology. He is Chief Executive Officer of Stellar IT Solutions, leading its government and commercial divisions, Chief Operating Officer of Stellar Venture Partners, and a co-founder of Stellar iDea Labs. He previously co-founded the fintech company Wild Oak Financial (dba Luav), serving eight years as its Chief Operating Officer before negotiating its sale to public company Digital Media Solutions (NYSE: DMS) in 2018. Before that he was a Special Agent with the FBI investigating complex financial crimes, and at FINRA he built the agency's first regulatory division for PIPE fraud and insider trading. He holds an MBA from Johns Hopkins Carey Business School and a BS in Finance from the University of Maryland.

Terry Lierman

President · Board member

As President of DnaK Therapeutics and a board member, Mr Lierman brings a career spent at the intersection of biomedical research, health policy and federal funding. He began at the National Institutes of Health and became Chief Administrator of the National Cancer Institute’s Division of Drug Research and Development, the office responsible for moving cancer compounds toward the clinic. He founded the Children’s Research Institute and co-founded the Pancreatic Cancer Action Network, now the largest organization of its kind. In government he served as Staff Director of the U.S. Senate Committee on Appropriations and as Chief of Staff to the Majority Leader of the U.S. House of Representatives.

Scientific leadership

Robert C. Gallo, MD Founder

Chief Scientist · Co-principal investigator · Board · Scientific advisory board

As Founder, Chief Scientist and Co-Principal Investigator at DnaK Therapeutics, Dr Gallo co-discovered HIV as the cause of AIDS and developed the HIV blood test that made diagnosis and safe blood transfusion possible worldwide. His laboratory identified HTLV, the first known human retrovirus, discovered Interleukin-2, and identified HHV-6. He has received the Lasker Award twice, among the highest honors in American medicine, and is one of the most cited scientists in the world. In 1996 he founded the Institute of Human Virology at the University of Maryland School of Medicine, and in 2011 he co-founded the Global Virus Network, a coalition of virologists working to prepare for and respond to viral threats. He continues to lead the scientific program at DnaK Therapeutics, building on more than a decade of research into bacterial DnaK and its role in cancer.

Davide Zella, PhD Founder

Co-principal investigator · Scientific advisory board

As a Co-Principal Investigator and founder of DnaK Therapeutics, Dr Zella is a professor at the Institute of Human Virology at the University of Maryland School of Medicine, where his research spans microbiology, virology, immunology, cancer biology and molecular biology. He has authored more than 50 peer-reviewed publications, with a focus on interferon-alpha, chemokine receptors, HIV replication and the tumor suppressor p53. It was his laboratory's work that first established that components of the human microbiota, particularly Mycoplasma and its chaperone protein DnaK, drive cellular transformation and undermine the effectiveness of anti-cancer drugs, forming the scientific foundation on which DnaK Therapeutics was built. He continues to lead laboratory research at the company alongside Dr Gallo and Dr Benedetti.

Francesca Benedetti, PhD Founder

Co-investigator · Scientific advisory board

As Co-Investigator and a founder of DnaK Therapeutics, Dr Benedetti works at the Institute of Human Virology at the University of Maryland School of Medicine, where her research focuses on cancer biology, molecular biology and in-vivo models of disease. She is first author on seven of the company's ten peer-reviewed publications, including the in-vivo studies demonstrating that bacterial DnaK increases DNA copy number variation and accelerates cancer development following DNA damage. Her work, conducted alongside Dr Gallo and Dr Zella, established the mechanistic link between tumor-associated bacteria and chemotherapy resistance that underlies the company's therapeutic and diagnostic programs. She has co-authored studies published in top-tier journals including PNAS and the Journal of Translational Medicine, and continues to lead in-vivo research at DnaK Therapeutics.

Christian Bréchot, MD, PhD

Board member · Scientific advisory board

Dr Bréchot serves DnaK Therapeutics as a board member and scientific advisor. He is a professor of medicine and senior associate dean for research at the University of South Florida, and vice-chair of the Global Virus Network, the organization he helped found alongside Dr Gallo. Over a career spanning more than three decades he led three major institutions: he served as President of Inserm, France's national institute for health and medical research, from 2001 to 2007; as vice-president of Institut Mérieux from 2008 to 2013; and as President of the Institut Pasteur from 2013 to 2017. His research expertise spans hepatology, virology and oncology, with a particular focus on the viral causes of liver cancer. He brings this international public-health and research-institution leadership experience to DnaK Therapeutics' scientific advisory board.

Eduardo Sotomayor, MD

Board member · Scientific advisory board

Dr Sotomayor serves DnaK Therapeutics as a board member and scientific advisor. He directs the Cancer Institute at Tampa General Hospital and is an internationally recognized expert in lymphoma research and treatment, and a pioneer in the fields of cancer immunology and immunotherapy. He previously directed the George Washington University Cancer Center, where he built a research program spanning basic, translational and clinical cancer research. It was Dr Sotomayor who recruited Dr Gallo and his research team to the University of South Florida, a move that helped establish the institutional relationships now supporting DnaK Therapeutics' work in Tampa. His clinical and research background in oncology gives the company's scientific advisory board direct experience translating laboratory discovery into cancer treatment.

Board of directors

DnaK Therapeutics is governed by a seven-member board: Dr Robert C. Gallo, Dr Christian Bréchot, Dipak Thakker, Dr Eduardo Sotomayor, Joshua Sircus, Mathew Evins and Terry Lierman. Mr Thakker and Mr Evins serve as co-chairs.